Document:

EX-10.1

 Exhibit 10.1 

Amendment No. 1 to Amended and Restated Advisory Agreement 

THIS AMENDMENT NO. 1 TO AMENDED AND RESTATED ADVISORY AGREEMENT (this “Amendment”), dated and effective as of Sept. 28, 2018,
is entered into by and among Rodin Income Trust, Inc., a Maryland corporation (the “Company”), Rodin Income Trust Operating Partnership, L.P., a Delaware limited partnership (the “Operating Partnership”), Rodin
Income Advisors, LLC, a Delaware limited liability company (the “Advisor”) and, solely with respect to Article 13 and Section 9.03 of the Advisory Agreement (as defined below), Cantor Fitzgerald Investors, LLC, a Delaware
limited liability company (the “Sponsor”), and, solely with respect to Section 9.03 Advisory Agreement, Rodin Income Trust OP Holdings, LLC, a Delaware limited liability company (the “Special Unit
Holder”). The Company, the Operating Partnership, the Advisor, the Sponsor and the Special Unit Holder are collectively referred to as the “Parties.” Capitalized terms used but not defined herein shall have the meanings
ascribed to such terms in the Advisory Agreement. 
 WHEREAS, the Parties entered into that certain Amended and Restated Advisory Agreement
(the “Advisory Agreement”), dated as of September 28, 2018, for an initial term of one year, pursuant to which the Advisor agreed to provide certain services to the Company; 

WHEREAS, the Advisory Agreement may be renewed for an unlimited number of successive one-year terms
upon mutual consent of the Parties, provided that the renewal is approved by a majority of the independent directors of the Company (also being all of the members of the Audit Committee of the Board of Directors of the Company); 

WHEREAS, the parties desire to enter into this Amendment (i) to extend the current term of the Advisory Agreement from September 28,
2019 to September 28, 2020, and (ii) to reduce the amount of Asset Management Fees payable by the Company to the Advisor, upon the terms and subject to the conditions hereinafter set forth; and 

WHEREAS, all of the independent directors of the Company (also being all of the members of the Audit Committee of the Board of Directors of
the Company) desire to amend the Advisory Agreement (i) to extend the current term of the Advisory Agreement from September 28, 2019 to September 28, 2020 and (ii) to reduce the amount of Asset Management Fees payable by the Company to the
Advisor. 
 NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants and agreements contained herein, and for other
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows: 
 1.
Effective as of the date hereof, the current term of the Advisory Agreement is hereby extended from September 28, 2019 to September 28, 2020. 

2. Section 8.02 of the Advisory Agreement is hereby superseded and replaced in its entirety with the following: 

“8.02 Asset Management Fees. The Company shall pay the Advisor or its Affiliates as compensation for the services described in
Section 3.03 hereof a monthly fee (the “Asset Management Fee”) in an amount equal to one-twelfth of 1.20% of the Company’s most recently disclosed NAV as
of the end of each month. The Advisor shall submit a monthly invoice to the Company, accompanied by a computation of the Asset Management Fee for the applicable month. The Asset Management Fee shall generally be payable on the last day of the month
that immediately follows the month in which such Asset Management Fee was earned, or the first business day following the last day of such month. However, payment of the Asset Management Fee may be deferred or waived, in whole or in part (or
received in Shares) in the sole discretion of the Advisor. Any such deferred or waived Asset Management Fees shall be paid to the Advisor or its Affiliates without interest at such subsequent date as the Advisor shall request.” 

 3. This Amendment constitutes an amendment to the Advisory Agreement. Except as set forth in
this Amendment, all of the provisions of the Advisory Agreement shall continue in full force and effect in accordance with their terms. In the event of any conflict between the provisions of the Advisory Agreement and the provisions of this
Amendment, the provisions of this Amendment shall control. 
 4. This Amendment (a) shall be binding upon the Parties and their
respective successors and assigns, (b) may be executed in several counterparts, each of which counterpart, when so executed and delivered, shall constitute an original agreement, and all such separate counterparts shall constitute but one and
the same agreement, and (c) together with the Advisory Agreement, embodies the entire agreement and understanding between the parties with respect to the subject matter hereof and supersedes all prior agreements, consents and understandings
relating to such subject matter. 
 [Signature Page Follows] 

  
 2 

 IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date
and year first above written. 
  

			
	RODIN INCOME TRUST, INC.
		
	By:	 	/s/ Steven Bisgay
	Name: 	 	Steven Bisgay
	Title:	 	Chief Financial Officer
	
	RODIN INCOME TRUST OPERATING PARTNERSHIP, L.P.,
		
	By:	 	 Rodin Income Trust, Inc.,
 its General
Partner

		
	By:	 	/s/ Steven Bisgay
	Name:	 	Steven Bisgay
	Title	 	Chief Financial Officer
	
	RODIN INCOME ADVISORS, LLC
		
	By:	 	/s/ Steven Bisgay
	Name:	 	Steven Bisgay
	Title:	 	Chief Financial Officer

  

			
	Solely with respect to Article 13 and Section 9.03 of the Advisory Agreement:
	
	CANTOR FITZGERALD INVESTORS, LLC

			
		
	By:	 	/s/ Steven Bisgay
	Name: 	 	Steven Bisgay
	Title:	 	Chief Financial Officer

			
	
	Solely with respect to Section 9.03 of the Advisory Agreement:
	
	RODIN INCOME TRUST OP HOLDINGS, LLC

			
		
	By:	 	/s/ Steven Bisgay
	Name: 	 	Steven Bisgay
	Title:	 	Chief Financial Officer

 [Signature page to Amendment No. 1 to Amended and Restated Advisory Agreement—Rodin Income Trust,
Inc.]ipix_ex41.htm

EXHIBIT 4.1
 
DESCRIPTION OF THE REGISTRANT’S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES
EXCHANGE ACT OF 1934
 
Innovation Pharmaceuticals Inc. (the “Company,” “we,” “our,” or “us”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: our Class A common stock.
 
DESCRIPTION OF CAPITAL STOCK
 
The following summary of the terms of our capital stock is based upon our Amended and Restated Articles of Incorporation (the “Articles of Incorporation”) and our Amended and Restated Bylaws (the “Bylaws”). The summary is not complete, and is qualified by reference to our Articles of Incorporation and our Bylaws. We encourage you to read our Articles of Incorporation, our Bylaws and the applicable provisions of the Nevada Revised Statutes for additional information.
 
Authorized Shares of Capital Stock
 
Our authorized capital stock consists of 600 million shares of Class A common stock, $0.0001 par value per share; 100 million shares of Class B common stock, par value $0.0001 per share; and 10 million shares of preferred stock, par value $0.001 per share. 
 
Quotation
 
Our Class A common stock is quoted on the OTCQB under the symbol “IPIX.”
 
Voting Rights
 
Each holder of Class A common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors, and each holder does not have cumulative voting rights. Each holder of Class B common stock is entitled to ten votes for each share on all matters submitted to a vote of the stockholders, and subject to the limitations provided by law and subject to any voting rights applicable to shares of preferred stock, the holders of shares of the Class A common stock and Class B common stock vote together as a single class, together with the holders of any shares of the preferred stock which are entitled to vote, and not as a separate class.
 
Dividend Rights
 
Subject to preferences that may be applicable to any then outstanding preferred stock, holders of Class A common stock are entitled to receive ratably those dividends, if any, as may be declared from time to time by the board of directors out of legally available funds.
 
Rights upon Liquidation
 
In the event of our liquidation, dissolution or winding up, holders of Class A common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any outstanding shares of preferred stock.
 
	 
	1
	
 
	 

 
Other Rights and Preferences
 
Holders of Class A common stock do not have preemptive or conversion rights or other subscription rights, and there are no redemption or sinking fund provisions applicable to the Class A common stock. All outstanding shares of Class A common stock are fully paid and nonassessable. The rights, preferences and privileges of the holders of Class A common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock currently outstanding or which we may designate in the future.
 
Transfer Agent and Registrar
 
West Coast Stock Transfer, Inc. is the transfer agent and registrar for our Class A common stock.
 
Certain Anti-Takeover Effects
 
Certain provisions of our Articles of Incorporation and Bylaws may be deemed to have an anti-takeover effect.
 
Advance Notice Requirements for Stockholder Proposals and Director Nominations. Our Bylaws provide advance notice procedures for stockholders seeking to bring business before meetings of our stockholders or to nominate candidates for election as directors at our stockholder meetings and specify certain requirements regarding the form and content of a stockholder’s notice. These provisions might preclude our stockholders from bringing matters before our stockholder meetings or from making nominations for directors at our stockholder meetings if the proper procedures are not followed. 
 
Additional Authorized Shares of Capital Stock. The additional shares of authorized common stock and preferred stock available for issuance under our Articles of Incorporation could be issued at such times, under such circumstances and with such terms and conditions as to impede a change in control.
 
Effect of Preferred Stock. Our board of directors is authorized to approve the issuance of preferred stock without stockholder approval and to determine the number of shares, the designations and the relative preferences, rights, restrictions and qualifications of any class or series of preferred stock. As a result, our board of directors could, without stockholder approval, authorize the issuance of preferred stock with voting, dividend, redemption, liquidation, sinking fund, conversion and other rights that could proportionately reduce, minimize or otherwise adversely affect the voting power and other rights of holders of capital stock or other classes or series of preferred stock or that could have the effect of delaying, deferring or preventing a change in control.
 
	 
	2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]